Table 4

Cyclin D1 protein expression in ACF and non-ACF Cryptsa

Treatment groupACF cryptsNon-ACF crypts
AOM486 ± 210b,c252 ± 110b
AOM+ UDCA137 ± 87d87 ± 43e
AOM+ F6-D367 ± 24d104 ± 53e
  • a Cyclin D1 was assessed by quantitative Western blotting as described in the “Materials and Methods” (n = 6 animals in each group, with 4 ACF and 4 non-ACF biopsies from each carcinogen-treated rat and 4 normal biopsies from each of the control groups). Data are expressed as % cyclin D1 in normal crypts from vehicle-treated rats (means ± SD). Cyclin D1 expression did not differ among the saline-treated unsupplemented rats and UDCA and F6-D3-supplemented rats.

  • b P < 0.05 compared with control.

  • c P < 0.05, compared with non-ACF crypts in AOM-alone group.

  • d P < 0.05, compared with ACF in AOM-alone group.

  • e P < 0.05, compared with non-ACF crypts in AOM-alone group.